These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 3573071

  • 1. Lack of effect of deferoxamine, dimethyl sulfoxide, and catalase on monocrotaline pyrrole pulmonary injury.
    Bruner LH, Johnson K, Carpenter LJ, Roth RA.
    J Toxicol Environ Health; 1987; 21(1-2):205-17. PubMed ID: 3573071
    [Abstract] [Full Text] [Related]

  • 2. Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin.
    Ganey PE, Sprugel KH, Hadley KB, Roth RA.
    J Pharmacol Exp Ther; 1986 Apr; 237(1):226-31. PubMed ID: 2937908
    [Abstract] [Full Text] [Related]

  • 3. Lactate dehydrogenase activity and isozyme patterns in tissues and bronchoalveolar lavage fluid from rats treated with monocrotaline pyrrole.
    Schultze AE, Gunaga KP, Wagner JG, Hoorn CM, Moorehead WR, Roth RA.
    Toxicol Appl Pharmacol; 1994 Jun; 126(2):301-10. PubMed ID: 8209383
    [Abstract] [Full Text] [Related]

  • 4. Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole.
    Schultze AE, Roth RA.
    Toxicol Appl Pharmacol; 1993 Jul; 121(1):129-37. PubMed ID: 7687795
    [Abstract] [Full Text] [Related]

  • 5. Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats.
    White SM, Wagner JG, Roth RA.
    Toxicol Appl Pharmacol; 1989 Jun 15; 99(2):302-13. PubMed ID: 2734793
    [Abstract] [Full Text] [Related]

  • 6. Complement is not involved in monocrotaline pyrrole-induced pulmonary injury.
    Bruner LH, Johnson KJ, Till GO, Roth RA.
    Am J Physiol; 1988 Feb 15; 254(2 Pt 2):H258-64. PubMed ID: 3344816
    [Abstract] [Full Text] [Related]

  • 7. The effect of immunosuppressants and adoptive transfer in monocrotaline pyrrole pneumotoxicity.
    Bruner LH, Bull RW, Roth RA.
    Toxicol Appl Pharmacol; 1987 Oct 15; 91(1):1-12. PubMed ID: 3672514
    [Abstract] [Full Text] [Related]

  • 8. 6-Ketoprostaglandin F1 alpha and thromboxane B2 in isolated, blood-perfused lungs from monocrotaline pyrrole-treated rats.
    Ganey PE, Roth RA.
    J Toxicol Environ Health; 1988 Oct 15; 23(1):127-37. PubMed ID: 3336057
    [Abstract] [Full Text] [Related]

  • 9. Effects of monocrotaline pyrrole on cultured rat pulmonary endothelium.
    Hoorn CM, Wagner JG, Roth RA.
    Toxicol Appl Pharmacol; 1993 Jun 15; 120(2):281-7. PubMed ID: 8511798
    [Abstract] [Full Text] [Related]

  • 10. Injury to the isolated, perfused lung by exposure in vitro to monocrotaline pyrrole.
    Hilliker KS, Roth RA.
    Exp Lung Res; 1985 Jun 15; 8(4):201-12. PubMed ID: 4043006
    [Abstract] [Full Text] [Related]

  • 11. An evaluation of procoagulant activity in the peripheral blood of rats treated with monocrotaline pyrrole.
    Schultze AE, Wagner JG, Roth RA.
    Toxicol Appl Pharmacol; 1991 Jul 15; 109(3):421-31. PubMed ID: 1830177
    [Abstract] [Full Text] [Related]

  • 12. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension.
    Hilliker KS, Bell TG, Lorimer D, Roth RA.
    Am J Physiol; 1984 Jun 15; 246(6 Pt 2):H747-53. PubMed ID: 6742140
    [Abstract] [Full Text] [Related]

  • 13. Early indications of monocrotaline pyrrole-induced lung injury in rats.
    Schultze AE, Wagner JG, White SM, Roth RA.
    Toxicol Appl Pharmacol; 1991 Jun 01; 109(1):41-50. PubMed ID: 2038748
    [Abstract] [Full Text] [Related]

  • 14. Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia.
    Ganey PE, Sprugel KH, White SM, Wagner JG, Roth RA.
    Am J Physiol; 1988 Nov 01; 255(5 Pt 2):H1165-72. PubMed ID: 3189578
    [Abstract] [Full Text] [Related]

  • 15. Effects of monocrotaline and monocrotaline pyrrole on 5-hydroxytryptamine and paraquat uptake by lung slices.
    Hilliker KS, Garcia CM, Roth RA.
    Res Commun Chem Pathol Pharmacol; 1983 May 01; 40(2):179-97. PubMed ID: 6410470
    [Abstract] [Full Text] [Related]

  • 16. Procoagulant and fibrinolytic properties of bovine endothelial cells treated with monocrotaline pyrrole.
    Schultze AE, Roth RA.
    Toxicol Appl Pharmacol; 1993 Sep 01; 122(1):7-15. PubMed ID: 8378934
    [Abstract] [Full Text] [Related]

  • 17. Monocrotaline pyrrole-induced pulmonary hypertension in fawn-hooded rats with platelet storage pool deficiency: 5-hydroxytryptamine uptake by isolated, perfused lungs.
    Hilliker KS, Bell TG, Roth RA.
    Thromb Haemost; 1983 Dec 30; 50(4):844-7. PubMed ID: 6665765
    [Abstract] [Full Text] [Related]

  • 18. COR pulmonale is caused by monocrotaline and dehydromonocrotaline, but not by glutathione or cysteine conjugates of dihydropyrrolizine.
    Pan LC, Wilson DW, Lamé MW, Jones AD, Segall HJ.
    Toxicol Appl Pharmacol; 1993 Jan 30; 118(1):87-97. PubMed ID: 8430429
    [Abstract] [Full Text] [Related]

  • 19. Pulmonary platelet sequestration is increased following monocrotaline pyrrole treatment of rats.
    White SM, Roth RA.
    Toxicol Appl Pharmacol; 1988 Dec 30; 96(3):465-75. PubMed ID: 2974653
    [Abstract] [Full Text] [Related]

  • 20. Development of morphologic, hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole.
    Reindel JF, Ganey PE, Wagner JG, Slocombe RF, Roth RA.
    Toxicol Appl Pharmacol; 1990 Nov 30; 106(2):179-200. PubMed ID: 2256110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.